Market Place
Sourcing Support
Dianthus Issues Nasdaq-Compliant Inducement Grants
01 May 2026 //
GLOBENEWSWIRE
Dianthus Therapeutics Reveals Inducement Grants Per Nasdaq LR
06 Apr 2026 //
GLOBENEWSWIRE
Dianthus Therapeutics Closes $719M Upsized Offering
12 Mar 2026 //
GLOBENEWSWIRE
Dianthus Early GO In Ph3 Claseprubart CIDP Trial
09 Mar 2026 //
GLOBENEWSWIRE
Dianthus Therapeutics Plans $400M Public Offering
09 Mar 2026 //
GLOBENEWSWIRE
Dianthus Therapeutics Highlights Recent Business Achievements
09 Mar 2026 //
GLOBENEWSWIRE
Dianthus Therapeutics to Host Conference Call and Webcast
08 Mar 2026 //
GLOBENEWSWIRE
Dianthus Therapeutics Announces Nasdaq Inducement Grants
03 Mar 2026 //
GLOBENEWSWIRE
Dianthus Therapeutics at TD Cowen 46th Annual Healthcare Conf
24 Feb 2026 //
GLOBENEWSWIRE
Dianthus Therapeutics Joins Guggenheim Biotech Summit 2026
05 Feb 2026 //
GLOBENEWSWIRE
Dianthus Therapeutics Joins 44th JP Morgan Healthcare Conference
05 Jan 2026 //
GLOBENEWSWIRE
Leads Biolabs & Dianthus Therapeutics Start Phase 1 Trial
23 Dec 2025 //
GLOBENEWSWIRE
Dianthus Therapeutics at 8th Evercore Healthcare Conference
24 Nov 2025 //
GLOBENEWSWIRE
Dianthus Therapeutics Showcases Business Successes, Reveals Q3
05 Nov 2025 //
GLOBENEWSWIRE
Dianthus Therapeutics Joins Four Investor Conferences In November
04 Nov 2025 //
GLOBENEWSWIRE
Dianthus Therapeutics Showcases Latest Claseprubart Data at 2025
29 Oct 2025 //
GLOBENEWSWIRE
Dianthus Therapeutics Licenses DNTH212, To Leads Biolabs
16 Oct 2025 //
GLOBENEWSWIRE
Dianthus Therapeutics To Present Claseprubart Data At 2025 AANEM
02 Oct 2025 //
GLOBENEWSWIRE
Dianthus Therapeutics Closes Upsized $288M Public Offering
11 Sep 2025 //
GLOBENEWSWIRE
Dianthus Reports Positive Ph 2 Data for Claseprubart
08 Sep 2025 //
GLOBENEWSWIRE
Dianthus Therapeutics Proposes $150M Public Offering
08 Sep 2025 //
GLOBENEWSWIRE
Dianthus Therapeutics to Host call for DNTH103 Ph 2 MaGic Trial
07 Sep 2025 //
GLOBENEWSWIRE
Dianthus Therapeutics highlights recent achievements, reports Q2
07 Aug 2025 //
GLOBENEWSWIRE
Dianthus Therapeutics at Jefferies Global Health Conference
29 May 2025 //
GLOBENEWSWIRE
Dianthus Therapeutics Appoints Simon Read, Ph.D., to Board
22 May 2025 //
GLOBENEWSWIRE
Dianthus Therapeutics Reports Q1 Financial Results and Achievemen
12 May 2025 //
GLOBENEWSWIRE
Dianthus Therapeutics Completes Enrollment Ph 2 Trial of DNTH103
05 May 2025 //
GLOBENEWSWIRE
Dianthus Therapeutics to Join Two Investor Events
29 Apr 2025 //
GLOBENEWSWIRE
Dianthus Therapeutics Reports Q4 and FY 2024 Financial Results
11 Mar 2025 //
GLOBENEWSWIRE
Dianthus Therapeutics to Join Two Investor Conferences
26 Feb 2025 //
GLOBENEWSWIRE
Dianthus Therapeutics to Presentations at Two Investor Conferences
30 Jan 2025 //
GLOBENEWSWIRE
Dianthus to Present at 43rd Annual J.P. Morgan Conference
08 Jan 2025 //
GLOBENEWSWIRE
Dianthus Therapeutics Reports Q3 2024 Results & Achievements
07 Nov 2024 //
GLOBENEWSWIRE
Dianthus Therapeutics to Attend 3 Upcoming Healthcare Conferences
04 Nov 2024 //
GLOBENEWSWIRE
Dianthus Announces Two Presentations For DNTH103 At AANEM Meeting
15 Oct 2024 //
GLOBENEWSWIRE
Dianthus To Attend Three September Investor Conferences
04 Sep 2024 //
GLOBENEWSWIRE
Dianthus Therapeutics Reports Q2 Results And Business Achievements
08 Aug 2024 //
GLOBENEWSWIRE
Dianthus: DNTH103 Oral Presentation At AAN 2024
11 Apr 2024 //
GLOBENEWSWIRE
